Abstract 451P
Background
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. To reduce the risk of an infusion-related reaction (IRR) with ramucirumab, H1-antihistamines are recommended as premedication. However, IRR is hardly observed in clinical practice in the ramucirumab regimen. The H1-antihistamines have several side effects, such as drowsiness and dizziness, and the use of H1-antihistamines might be restricted for the patients who need to drive a car or for elderly patients. The aim of this study was to investigate the safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancer.
Methods
We retrospectively reviewed the solid tumour patients who received ramucirumab, including regimen without H1-antihistamines at our institution between 2017 and 2019. The patients who received antiemetic steroid for cytotoxic chemotherapy was also included. The primary endpoint was the incidence of IRR during the infusion in the first cycle. The secondary endpoints were the incidence of IRR at any time and other ramucirumab related adverse events.
Results
Of the 51 patients enrolled (median age, 69.5 years; range 41 - 83), 28 (55%) were male. The origins of cancer were gastric cancer (n = 22), lung cancer (n = 26), and colon cancer (n = 3), respectively. Forty-two patients (82%) received ramucirumab in combination with antiemetic steroid for cytotoxic chemotherapy, and nine patients (18%) received ramucirumab monotherapy without steroid. No IRR was observed in this study (IRR rate, 0%; 95% CI 0 - 0.69). Among the overall 272 infusions, there were no events of IRRs or other ramucirumab related adverse events.
Conclusions
There was no IRRs without H1-antihistamines in our retrospective study. Ramucirumab without H1-antihistamines as premedication would be a favourable option for the patients who had trouble with the side effects of H1 antihistamine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract